Looking ahead, 2009 will be a year of
many activities at Clinuvel. We have
been preparing various corporate
activities surrounding the development
of afamelanotide which we will able to
reveal by Q1.
We wish you, in anticipation of the
newsflow on the company, a healthy
and prosperous 2009.
Philippe Wolgen, MBA, MD
CEO
jan 2009
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.73 |
Change
-0.570(3.99%) |
Mkt cap ! $687.8M | |||
| Open | High | Low | Value | Volume |
| $14.21 | $14.25 | $13.70 | $1.202M | 86.43K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 3001 | $13.71 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.73 | 205 | 5 |
View Market Depth
| Last trade - 10.51am 27/09/2024 (20 minute delay) ? |
| CUV (ASX) Chart |